Suven Pharma rebranded as Cohance Lifesciences

Published On 2025-05-08 08:15 GMT   |   Update On 2025-05-08 08:15 GMT

Hyderabad: Suven Pharmaceuticals Limited, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences Limited.

According to the Company, the Cohance name captures the organization’s commitment to collaborate with global innovators to enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.

"The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world " said Cohance Executive Chairman, Vivek Sharma.

Advertisement

The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals Limited” to “Cohance Lifesciences Limited”, with effect from May 7, 2025.

Read also: Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

The change of name has been carried on pursuant to the Scheme of Amalgamation.

"The Company would make necessary application to the BSE Limited and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals Limited” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences Limited”," Suven stated in a release.

Read also: Suven Pharma appoints Vivek Sharma as new Executive Chairman

Cohance Lifesciences, formerly Suven Pharmaceuticals Ltd, is a technology-driven CDMO, providing integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators. The company has over 100 active projects and a pipeline of late-stage molecules. 

Read also: First subjects dosed in Phase-1 clinical trial of Cognitive Disorder drug SUVN-I6107: Suven Life Sciences

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News